• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 10, Issue 2
  3. Author

Online ISSN: 2515-8260

Volume10, Issue2

Outcomes Of Intralesional Bleomycin For The Management Of Cutaneous Low Flow Venous Malformations

    Babar Zargar, Heena Masrat, Aaliya Tabasum .

European Journal of Molecular & Clinical Medicine, 2023, Volume 10, Issue 2, Pages 128-132

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: Venous malformations are a type of vascular malformation with abnormally developed vein, venules and venous capillaries bunching together to produce soft cystic reducible masses containing venous blood. They account for about two third of vascular malformations. It may involve skin, mucosa or any other part of the body. The aim of this study was to evaluate the efficacy and safety of intralesional bleomycin sclerotherapy in low flow venous malformations.
Materials and Methods: During 2019- 2022, 213 patients with cutaneous venous malformations were treated with bleomycin sclerotherapy at a tertiary care hospital. The diagnosis of venous malformation was made on the basis of clinical history and physical examination and confirmed by doppler ultrasonographic examination Only patients with low flow venous malformations were treated with intralesional bleomycin sclerotherapy.
Results: All were treated with intralesional bleomycin (0.1 I.U/ kg body weight) on an outpatient basis. Complete resolution (grade 4) was observed in 76(35.6%) patients and almost complete resolution (grade 3) with very minimal residual lesion or pigmentation was seen in 89(41.7%) patients thus producing a complete or near complete response in 77.3% patients.
Conclusion: Intralesional bleomycin sclerotherapy is an excellent treatment modality for the management of low flow venous malformations with very low procedural morbidity.
Keywords:
    venous malformations bleomycin sclerotherapy intralesional
  • PDF (312 K)
  • XML
(2023). Outcomes Of Intralesional Bleomycin For The Management Of Cutaneous Low Flow Venous Malformations. European Journal of Molecular & Clinical Medicine, 10(2), 128-132.
Babar Zargar, Heena Masrat, Aaliya Tabasum .. "Outcomes Of Intralesional Bleomycin For The Management Of Cutaneous Low Flow Venous Malformations". European Journal of Molecular & Clinical Medicine, 10, 2, 2023, 128-132.
(2023). 'Outcomes Of Intralesional Bleomycin For The Management Of Cutaneous Low Flow Venous Malformations', European Journal of Molecular & Clinical Medicine, 10(2), pp. 128-132.
Outcomes Of Intralesional Bleomycin For The Management Of Cutaneous Low Flow Venous Malformations. European Journal of Molecular & Clinical Medicine, 2023; 10(2): 128-132.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 18
  • PDF Download: 79
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus